Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 679 across all filing types
Latest filing 2025-09-22 Interim / Quarterly Rep…
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
Rapport d'activité financier et semestriel 2025
Interim / Quarterly Report Classification · 100% confidence The document is a 'Rapport d'Activité et Financier Semestriel' (Half-Yearly Activity and Financial Report) for the period ending June 30, 2025. It contains comprehensive financial statements (consolidated balance sheet, income statement, cash flow, etc.), management's discussion and analysis of the business, and an audit report. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-09-22 French
Attestation de la personne responsable associée au rapport d'activité et financier semestriel 2025
Regulatory Filings Classification · 95% confidence The document is a short attestation letter signed by the CEO (Pascal Prigent) confirming the accuracy of the consolidated financial statements and the interim activity report. It does not contain the actual financial statements or substantive financial data itself. According to the 'Certification Rule', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a report. H1 2025
2025-09-22 French
GENFIT annonce l'arrêt de son programme VS-01 dans l'ACLF – le développement de VS-01 est recentré sur l'UCD
Regulatory Filings Classification · 95% confidence The document is a press release from GENFIT announcing the discontinuation of a specific clinical trial program (VS-01 in ACLF) and the strategic redirection of that program to a different indication (UCD). It details the clinical rationale, the impact on the company's financial outlook, and future pipeline updates. This is a standard corporate announcement regarding business operations and clinical trial status, which falls under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement that does not fit into more specific categories like M&A, Earnings Release, or Director's Dealing.
2025-09-19 French
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
Regulatory Filings Classification · 95% confidence The document is a press release issued by GENFIT announcing the discontinuation of a specific clinical program (VS-01 in ACLF) and the reprioritization of its development pipeline. It discusses the clinical rationale, the impact on operating expenses, and provides forward-looking statements regarding the company's financial outlook. This type of corporate announcement regarding operational strategy and clinical trial status is best classified as a Regulatory Filing (RNS) as it serves as a general corporate update that does not fit into more specific categories like Earnings Release (which would focus on quarterly financial results) or M&A Activity.
2025-09-19 English
Genfit : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
Transaction in Own Shares Classification · 100% confidence The document is a press release from GENFIT announcing the semi-annual report of its liquidity contract with Crédit Industriel et Commercial. It provides a summary of transactions (purchases and sales of shares) conducted under this contract for the first half of 2025. This type of disclosure, which details the company's activity in its own shares through a liquidity provider, is classified as a 'Transaction in Own Shares' (POS) report.
2025-07-08 French
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Transaction in Own Shares Classification · 95% confidence The document is a press release from GENFIT detailing the half-year report of its liquidity contract with Crédit Industriel et Commercial. It provides specific data on share transactions (buy/sell side) and the remaining balance on the liquidity account as of June 30, 2025. This type of disclosure, which reports on the company's activity regarding its own shares under a liquidity agreement, is classified as a 'Transaction in Own Shares' (POS) filing. H1 2025
2025-07-08 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.